In a comparison study, benefits of nurse-led preoperative counseling and follow-up care was significantly greater compared with surgeon-led or no counseling models.
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will…
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years…
A full day of programming is dedicated to the tailored treatments that are required to care for this uniquely vulnerable patient population, explains Michael Verneris,…
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to work against tumors, according to a study published in Science Advances.
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.
A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained…
Blastic plasmacytoid dendritic cell neoplasm is a rare but aggressive malignancy that arises from precursors of plasmacytoid dendritic cells and typically
The FDA approved mirdametinib for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.
